February 1, 2005 Public Meeting

1

Update on CDISC Study Data Tabulation Model

Randy Levin, M.D. Director for Health and Regulatory Data Standards Food and Drug Administration


Why Standards?

- Improve patient safety and reduced costs by reducing time to market for safe and effective treatments
 - Improve efficiency of evaluation of safety and efficacy of investigational treatments
 - Facilitate communication between regulatory authority and applicant
 - Facilitate development of efficient review environment (e.g., access to data, orientation, redundancy, training, analysis tools)
 - Improve efficiency for clinical research
 - Facilitate design and conduct of clinical trials
 - Facilitate communication between researchers and study sponsor (e.g., between CRO and drug company)
 - Integration with the electronic health record


CDISC SDTM in Health Information Technology Initiatives

- Regulatory electronic submissions
- Critical Path
- Health IT Strategic Framework
- Electronic Health Record
- Others

Target Study Data Environment



Healthcare Standards – HL7 Electronic Health Record



Timeline to Target

- Steps
 - Step 0 No standards
 - Step 1 SDTM v3.1 \leftarrow we are here
 - Step 2 JANUS and Smart Tools
 - Step 3 SDTM enhancements
- Timeline dependencies
 - JANUS implementation
 - Smart tool development and implementation
 - SDTM enhancements and associated JANUS and tool enhancements
 - Reviewer requirements

Timeline Dependencies Status

- JANUS
 - Physical database model completed (IBM CRADA)
 - Negotiations to set up database underway
- Smart Tools
 - Patient profile available to work off of SAS XPT files (PPD Informatics Patient Profiles)
 - SDTM v 3.1 data validation tool available in mid 2005 (Lincoln Technologies - WebSDM)
 - Prototype loader and front end for clinical reviewers (Lincoln Technologies - WebSDM)
 - Viewing tool for pharm/tox under development (PharmQuest ToxVision)
 - Loader, viewing and export tools from JANUS under development
 - Terminology server (NCI Enterprise Vocabulary Services)

Timeline Dependencies Status

- Exchange format
 - Metadata exchange format available 2005 (CDISC Define.xml)
 - Data, metadata and audit trail transport format under development (CDISC/HL7 XML)
- SDTM enhancements
 - Terminology under development (FDA, NCI, CDISC, HL7)
 - Additional protocol details under development (FDA, CDISC, NIH, HL7)
 - Analysis variables under development (FDA, CDISC)
 - Implementation guides under development Animal Tox (FDA, CDISC/SEND), Microbiology (FDA, CDISC), Pharmacokinetics (FDA, CDISC)
- Reviewer requirements
 - Training on SDTM implementation guides, define.xml
 - Training as tools become available

Recommendations

- Provide SDTM v 3.1 datasets
- Discuss the need for additional datasets with the reviewers by discipline
 - Pharm/tox
 - PK/PD
 - Micro
 - Medical
 - Statistical

Requirements

- HHS Regulatory Agenda inventory of all rulemaking actions under development or review (December 2004 Federal Register 69 FR 73119)
 - Submission of Standardized Electronic Study Data from Clinical Studies Evaluating Human Drugs and Biologics
 - Proposal would revise FDA regulations to require clinical study data to be provided in electronic format and require the use of standard data structure, terminology and code sets.
 - Legal authority: 21 USC 355; 21 USC 371: 42 USC 262
 - CFR Citation: 21 CFR 314.50; 21 CFR 601.12; 21 CFR 314.94
 - Timetable
 - Action NPRM
 - Date June 2005

Agenda

- 8:30 FDA Plans for Implementing SDTM Randy Levin
- 8:55 Current Status of the CDISC SDTM and enhancements Wayne Kubick
- 9:20 Current State of Trial Design Model Diane Wold
- 9:40 Applying the SDTM for non clinical and PK: Sponsor Perspective Fred Wood
- 10:00 Break
- 10:20 SDTM Submission: Sponsor perspective Bill Qubeck
- 10:50 Implementing SDTM -Tom Guinter and Dan Godoy
- 11:30 Applying SDTM for the JANUS Data Warehouse Norman Stockbridge
- 12:00 Lunch
- 1:00 FDA reviewer perspective Medical Officer Armando Oliva
- 1:30 FDA reviewer perspective Pharm/Tox reviewer Tom Papoian
- 1:50 FDA reviewer perspective Statistician Steve Wilson
- 2:30 Break
- 2:40 Q&A Panel Discussion All speakers